The Patent Finder

Terms ending in 2033

Atyr Pharma, Inc.

Every in-force patent on Atyr Pharma, Inc.'s record whose computed term ends in 2033, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleHolderStatusExpiresConfidence
US 12,497,466Compositions and Methods Comprising Histidyl-Trna Synthetase Splice Variants Having Non-Canonical Biological Activities
In force
 · High confidence
Pangu Biopharma LimitedIn forceHigh confidence
US 9,688,978Aspartyl-Trna Synthetase-Fc Conjugates
In force
 · High confidence
Atyr Pharma, Inc.In forceHigh confidence
US 9,822,353Pegylated Aspartyl-Trna Synthetase Polypeptides
In force
 · High confidence
Atyr Pharma, Inc.In forceHigh confidence
US 9,816,084Aspartyl-Trna Synthetases
In force
 · High confidence
Atyr Pharma, Inc.In forceHigh confidence
4 of 4 patents shown. Soonest term end first, then patent number.
3 of these are in force and held by Atyr Pharma, Inc..
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited